Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy

Cytokine

Volumn 61, Issue 3, 2013, Pages 755-758

  Braicu, E I ^a,d   Fotopoulou, C ^a   Chekerov, R ^a   Richter, R ^a   Blohmer, J ^b   Kummel S ^c   Stamatian, F ^d   Yalcinkaya, I ^a   Mentze, M ^a   Lichtenegger, W ^a   Sehouli, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Sankt Gertrauden Hospital   (Germany)

^c KLINIKEN ESSEN MITTE   (Germany)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adhesion molecules; Angiogenesis; Cervical cancer; Clinical outcome; Overall survival

Indexed keywords

CARBOPLATIN; CISPLATIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1;

ABDOMINAL HYSTERECTOMY; ADULT; AGE; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PARAAORTIC LYMPHADENECTOMY; PELVIS LYMPHADENECTOMY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REFERENCE VALUE; UTERINE CERVIX CANCER; VAGINAL HYSTERECTOMY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84875380267     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.01.013     Document Type: Article

References (22)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Peto J., Gilham C., Deacon J., Taylor C., Evans C., Binns W., et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004, 91:942-953.
3. Cuzick J., Mayrand M.H., Ronco G., Snijders P., Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine 2006, 24(Suppl. 3):90-97. [Review].
4. Ronco G., Giorgi Rossi P. New paradigms in cervical cancer prevention: opportunities and risks. BMC Women's Health 2008, 8:23. [Review].
5. Frazer I.H., Leggatt G.R., Mattarollo S.R. Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 2011, 29:111-138. [Review].
6. Hazelbag S., Kenter G.G., Gorter A., Fleuren G.J. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 2004, 112:1020-1028.
7. Zhai Y., Hotary K.B., Nan B., Bosch F.X., Muñoz N., Weiss S.J., et al. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res 2005, 65:6543-6550.
8. Harry V.N., Gilbert F.J., Parkin D.E. Predicting the response of advanced cervical and ocarian tumors to therapy. Obstet Gynecol Surv 2009, 64:548-560.
9. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., West C.M.L. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. BJC 2000, 83:620-625.
10. Ferrara N., Heinsohn H., Walder C.E., Bunting S., Thomas G.R. The regulation of blood vessel growth by vascular endothelial growth factor. Ann N Y Acad Sci 1995, 752:246-256. [Review].
11. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001, 21:1104-1117. [Review].
12. Campo E., Merino M.J., Liotta L., Neumann R., Stetler-Stevenson W. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 1992, 23:1395-1401.
13. Libra M., Scalisi A., Vella N., Clementi S., Sorio R., Stivala F., et al. Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 2009, 34:897-903. [Review].
14. Brooks R., Kizer N., Nguyen L., Jaishuen A., Wanat K., Nugent E., et al. Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol 2010, 116:539-543.
15. Melendez N.D., Smoller B.R., Morgan M. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas. Mod Pathol 2003, 16:8-13.
16. Sehouli J., Blohmer J.U., Kuemmel S., Runnebaum I.B., Hartmann W., Richter R., et al. Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-intergroup Study. J Clin Oncol 2010, (Suppl. abstr 5005):28.
17. Van Trappen P.O., Steele D., Lowe D.G., Baithun S., Beasley N., Thiele W., et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003, 201:544-554.
18. Anne T.M., Taina T.H. Levels of circulating TIMP-2 and MMP2-TIMP2 complex are decreased in squamous cervical carcinoma. Obstet Gynecol Int 2010.
19. John A., Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001, 7:14-23.
20. Sheu B.C., Lien H.C., Ho H.N., Lin H.H., Chow S.N., Huang S.C., et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003, 63:6537-6542.
21. Davidson B., Goldberg I., Kopolovic J., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999, 73:372-382.
22. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, Suppl. 10:K29-K41. [Review].